Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ReViral
Biotech
Pfizer snaps up rights to RSV therapy left behind in ReViral buy
Pfizer, looking to lead in RSV, is going back to scoop up one therapy that was left on the table after this summer's ReViral deal.
Gabrielle Masson
Dec 19, 2022 11:23am
Pfizer nabs RSV biotech ReViral in quick $525M bolt-on
Apr 7, 2022 8:27am
RSV specialist ReViral hires ex-Dova leader as CEO
Jun 11, 2019 9:22am
ReViral raises $55M to run midphase RSV clinical trials
Aug 1, 2018 3:09am
British biotech ReViral hits goals in early RSV test
Feb 5, 2018 5:23am
